tbuckley/cabot-search huggingface dataset:
Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program
Authors: Jie-Bin Lew, Kate T Simms, Megan A Smith, Michaela Hall, Yoon-Jung Kang, Xiang Ming Xu, Michael Caruana, Louiza Sofia Velentzis, Tracey Bessell, Marion Saville, Ian Hammond, Karen Canfell
Journal: The Lancet Public Health (2017)

BackgroundAustralia's National Cervical Screening Program currently recommends cytological screening every 2 years for women aged 18–69 years. Human papillomavirus (HPV) vaccination was implemented in 2007 with high population coverage, and falls in high-grade lesions in young women have been reported extensively. This decline prompted a major review of the National Cervical Screening Program and new clinical management guidelines, for which we undertook this analysis.MethodsWe did effectiveness modelling and an economic assessment of potential new screening strategies, using a model of HPV transmission, vaccination, natural history, and cervical screening. First, we evaluated 132 screening strategies, including those based on cytology and primary HPV testing. Second, after a recommendation was made to adopt primary HPV screening with partial genotyping and direct referral to colposcopy of women positive for HPV16/18, we evaluated the final effect of HPV screening after incorporating new clinical guidelines for women positive for HPV. Both evaluations considered both unvaccinated and vaccinated cohorts.FindingsStrategies entailing HPV testing every 5 years and either partial genotyping for HPV16/18 or cytological co-testing were the most effective. One of the most effective and cost-effective strategies comprised primary HPV screening with referral of women positive for oncogenic HPV16/18 direct to colposcopy, with reflex cytological triage for women with other oncogenic types and direct referral for those in this group with high-grade cytological findings. After incorporating detailed clinical guidelines recommendations, this strategy is predicted to reduce cervical cancer incidence and mortality by 31% and 36%, respectively, in unvaccinated cohorts, and by 24% and 29%, respectively, in cohorts offered vaccination. Furthermore, this strategy is predicted to reduce costs by up to 19% for unvaccinated cohorts and 26% for cohorts offered vaccination, compared with the current programme.InterpretationPrimary HPV screening every 5 years with partial genotyping is predicted to be substantially more effective and potentially cost-saving compared with the current cytology-based screening programme undertaken every 2 years. These findings underpin the decision to transition to primary HPV screening with partial genotyping in the Australian National Cervical Screening Program, which will occur in May, 2017.FundingDepartment of Health, Australia.
A new device to monitor the intraoperative lower oesophagealsphincter pressure during the laparoscopic antirefluxsurgery-the feasibility study
Authors: Petr Kysela, Zdeněk Kala, Vladimír Procházka, Filip Marek, Jiří Dolina, Radek Kroupa
Journal: Gut (2009)

Number of manipulations with the probe and number of probe
diplacements was significantly lower in the newly designed
calibration probe thus giving probably more reliable values
according to which the surgeon forms the wrap. The desired of
the new device on the postoperative dysphagia occurence has to
be revalued yet.
Fludarabine and Busuphan (Flu-Bu) as Reduced Intensity-Conditioning (RIC) Regimen in HLA-Identical Sibling Allogeneic Hematopoietic Stem Transplantation (Allo-SCT) for Myeloid Malignancies. Results of a Prospective Multicenter Study.
Authors: David Valcarcel, Rodrigo Martino, Enrique Colado, Jesus Martin, Josep-Maria Ribera, Christelle Ferra, Antonia Sampol, Juan Besalduch, Paqui Inesta, Jose M. Moraleda, Teresa Bernal, Dolores Carrera, Jose L. Piñana, Dolores Caballero, Jorge Sierra
Journal: Blood (2006)
Cytokine Release from Peripheral Blood Mononuclear Cells upon Stimulation with the Culprit Drugs during Acute Stage of Severe Cutaneous Adverse Reactions
Authors: Jettanong Klaewsongkram, Pattarawat Thantiworasit, Nithikan Suthumchai, Pawinee Rerknimitr, Papapit Tuchinda, Leena Chularojanamontri, Ticha Rerkpattanapipat, Kumutnart Chanprapaph, Wareeporn Disphanurat, Panlop Chakkavittumrong, Napatra Tovanabutra, Chutika Srisuttiyakorn, Chonlaphat Sukasem, Yuttana Srinoulprasert
Journal: Journal of Allergy and Clinical Immunology (2017)
Effect of Reduced Renal Function on Time in Therapeutic Range Among Anticoagulated Atrial Fibrillation Patients
Authors: Anders Nissen Bonde, Gregory Y.H. Lip, Anne-Lise Kamper, Laila Staerk, Christian Torp-Pedersen, Gunnar Hilmar Gislason, Jonas Bjerring Olesen
Journal: Journal of the American College of Cardiology (2017)
PDCT-05. STEADY-STATE VISUAL EVOKED POTENTIALS TO BETTER ASSESS VISUAL FUNCTIONS IN CHILDREN WITH OPTIC PATHWAY GLIOMAS
Authors: Sébastien Perreault, Sarah Rassi, Dave Saint-Amour, Luis Ospina, Yvan Samson
Journal: Neuro-Oncology (2016)

Optic Pathway Gliomas (OPG) represent 4-6% of brain tumors in children. Magnetic resonance imaging (MRI) and visual acuity are usually used to evaluate clinical evolution and treatment response. Since the goal of treatment is to preserve vision, it is important to develop new rapid, reliable, and non-invasive techniques to objectively measure the integrity visual functions in patients with optic pathway gliomas. Using a new approach with steady state visual evoked potentials (ssVEP), we were able to simultaneously assess central and peripheral visual fields of participants. Two circular dartboard patterns from fovea to peripheral zones up to 32 degrees of eccentricity are presented to the patients at two different flickering frequencies 14.4 and 16 reversal/s. Each stimulation is presented at two different levels of contrast (96 and 30%) to maximise sensitivity. To assess visual field integrity, 8 blocks of 10 seconds are presented to the participants. Since the initiation of this pilot study, 14 controls and 4 patients with optic pathway gliomas have been enrolled and followed prospectively. The preliminary results indicate that the method is promising for evaluating the integrity of the visual field in visually impaired populations (i.e. children with OPGs). The next step of our project is to use this technique to measure visual functions in children with OPGs aged 4 to 21 years prospectively over a period of 12 months. We will compare ssVEP obtained with MRIs and standard assessments in neuro-ophthalmology, which includes visual acuity and optical coherence tomography. This new electrophysiology method could potentially improve the monitoring and management of patients with OPGs by reliably detecting subtle visual changes.
Associations of IGFBP3 SNPs, methylation and recurrence risk in patients with stage II colorectal cancer
Authors: Tao Fu, Fan Li, Jingwang Ye, Zhengyong Liu, Christopher L Wolfgang, Christine A Iacobuzio-Donahue, Weidong Tong, Baohua Liu, Nita Ahuja
Journal: Annals of Oncology (2016)
89P Questionnaire survey on patients' preference for orally disintegrating tablets or granules of S-1 in postoperative adjuvant treatment for breast cancer
Authors: I. Fukada, Y. Ito, T. Shibayama, K. Kobayashi, N. Teruya, S. Takahashi, R. Horii, F. Akiyama, T. Iwase, M. Toi, S. Ohno
Journal: Annals of Oncology (2016)
Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis
Authors: Nan Ding, Zhaojun Zhang, Wenyu Yang, Lan Ren, Yingchi Zhang, Jingliao Zhang, Zhanqi Li, Peihong Zhang, Xiaofan Zhu, Xiaojuan Chen, Xiangdong Fang
Journal: Genomics Proteomics & Bioinformatics (2017)

Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder in human bone marrow. Over 50% of patients with myelofibrosis have mutations in JAK2, MPL, or CALR. However, these mutations are rarely detected in children, suggesting a difference in the pathogenesis of childhood PMF. In this study, we investigated the response to drug treatment of a monozygotic twin pair with typical childhood PMF. The twin exhibited different clinical outcomes despite following the same treatment regimen. The transcriptomic profiles of patient samples after drug treatment (E2 and Y2) were significantly different between the twin pair, which is consistent with the observation that the drug treatment was effective only in the younger brother, despite the twin being genetically identical. Bioinformatics analysis of the drug-responsive genes showed that the JAK-STAT pathway was activated in the cured younger brother, which is opposite to the pathway inhibition observed in adult PMF cases following treatment. Moreover, apoptosis and cell cycle processes were both significantly influenced by drug treatment in the sample of younger brother (Y2), implying their potential association with the pathogenesis of childhood PMF. Gene mutations in JAK2, MPL, or CALR were not observed; however, mutations in genes including SRSF2 and SF3B1 occurred in this twin pair with childhood PMF. Gene fusion events were extensively screened in the twin pair samples and the occurrence of IGLV2-14-IGLL5 gene fusion was confirmed. The current study reported at transcriptomic level the different responses of monozygotic twin brothers with childhood PMF to the same androgen/prednisone treatment regimen providing new insights into the potential pathogenesis of childhood PMF for further research and clinical applications.
Effectiveness and Potential Strategies to Improve Outcomes Following Chemomobilization with Etoposide + G-CSF in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma
Authors: William A Wood, Julia Whitley, Ravi K Goyal, Paul M Brown, Andrew Sharf, Robert N Irons, Kamakshi Rao, Amber N Essenmacher, Jonathan Serody, James Coghill, Paul M. Armistead, Stefanie Sarantopoulos, Don A. Gabriel, Thomas C. Shea
Journal: Blood (2011)
Risk of secondary cancers after breast conserving therapy in Japan.
Authors: Kenshiro Shiraishi, Tomohiro Shinozaki
Journal: Journal of Clinical Oncology (2016)

256 Background: There is a growing body of evidence that vast majority of patients with early breast cancer who underwent breast conserving therapy (BCT) live their longer ‘cancer survivor’ lives through modern sophisticated treatment. Accordingly, second malignancies after BCT are on the rise, which are sticky dilemmas accompanied by additional anxiety and need for further medical care. Investigation of secondary malignancies should be made the first priority in Japan as the world's top country for longevity. Methods: In order to investigate the second malignancies after BCT, a cohort study was conducted based on our database from 1982 to mid-2015. Actuarial rates of second malignancies, overall (OS) and cause-specific survival (CSS), were calculated by using the Kaplan-Meier method. We calculated standardized incidence ratios (SIR) for each cancer type corresponding to the national registry. Results: 1,557 patients (49.5%) were followed-up for more than 10 years. At a median follow-up of 113 months, 180 patients had developed a second malignancy. The increases in risk were for leukemia (SIR: 3.89 (1.76–6.84)) and ovarian cancer (SIR: 3.65 (2.26–5.38)). Trends toward increased risk was seen in reno-ureteral cancer (SIR: 2.25 (0.96–4.08)) and endometrial cancer (SIR: 1.59 (0.92–2.43)) though it was not statistically significant. No increased risk was observed for other gastrointestinal and genitourinary cancer, malignant melanoma, lymphoma, thyroid or head and neck cancer. Overall 10-year cumulative incidence of OS was 93.3%, and overall 10-year cumulative incidence of CSS was 95.0%. Overall 10-year incidence of secondary cancer was 5.9%. A total number of secondary malignancies within 10 years was 157 and this number explained 84.4% of all cases observed during follow-up. Secondary cancers continued to occur afterward, and cumulative incidence at 15- and 20-years were 8.4% , and 9.6%, respectively. Conclusions: Secondary cancers after BCT continue to arise as long as patients survive. Given its nature of life-threatening to cancer survivors, attending care team must pay persistent attention to secondary malignancies especially in Japan with the longest life-span.
A High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Is Obesity a Risk Factor for APL? Implication of Targeted Therapy to Control Obesity and APL Prevention.
Authors: Julianne Qualtieri, Jason Tedesco, Bipin N. Savani, Gregory Ayers, Meera Kumar, John P. Greer, David R. Head, Nishitha Reddy
Journal: Blood (2009)
Functional consequence of cognitive impairment in survivors of childhood acute lymphoblastic leukemia (ALL): The role of cancer symptoms as mediators.
Authors: I-Chan Huang, Tara M. Brinkman, Yin Ting Cheung, Ching-Hon Pui, Melissa M. Hudson, Kevin R. Krull
Journal: Journal of Clinical Oncology (2016)

235 Background: Although cognitive impairment of childhood cancer survivors affects daily functional status, the mechanisms are less understood. This study aimed to examine the role of cancer symptoms on the association of cognitive impairment with functional status in childhood ALL survivors treated on a chemotherapy only protocol. Methods: 213 survivors (mean age = 14.8 years) were assessed at &gt; 5 years post-diagnosis. Testing included measures of executive function (Delis-Kaplan Executive Function System; Wechsler Intelligence Scale for Children-IV [WISC-IV]), processing speed (WISC-IV; Grooved Pegboard), visual-spatial processing (Wechsler Abbreviated Scale of Intelligence), memory span (WISC-IV), and attention (Conners CPT-II). Symptoms (e.g., pain, worry, cognitive, communication) and daily functional status (physical, emotional, social, school) were reported by parents using the PedsQL. Association of cognitive impairment with symptoms and functional status was tested using regression analyses. The extent to which cognitive impairment influences functional status through symptoms was tested using mediation analyses. Results: Cognitive impairment ( &gt; 1SD below age-adjusted norm) was identified in 18-41% of the survivors. Impaired executive function, processing speed, and memory span were associated with high cancer symptoms (all p’s &lt; 0.05), typically driven by perceived cognitive and communication problems. Impaired executive function, processing speed, visual-spatial processing, and memory span were associated with poor functional status (all p’s &lt; 0.05). In each cognitive domain, impairment was related to poor school function (all p’s &lt; 0.05). Impact of cognitive function (except attention) on overall functional status was mediated by overall cancer symptoms (all p’s &lt; 0.05). Conclusions: Although the frequency of impairment in survivors treated with chemotherapy was less than that seen with cranial irradiation, cognitive impairment is related to elevated cancer symptoms and decreased functional status. Mediation analyses suggest that cognitive function works through cancer symptoms to impact functional status.
Survival in BRAF-mutant metastatic melanoma in the real-world setting: results from the Dutch Melanoma Treatment Registry
Authors: M. Schouwenburg, A. Jochems, M. Aarts, Fvanden Berkmortel, Avanden Eertwegh, M. Franken, G. Groenewegen, J.-W. de Groot, J.B.A.G. Haanen, G. Hospers, E. Kapiteijn, R. Koornstra, W. Kruit, M. Louwman, D. Piersma, R. van Rijn, A.J. Ten Tije, G. Vreugdenhil, M. Wouters, J. van der Hoeven
Journal: Annals of Oncology (2016)
Placebo-Controlled Trials of C1-Inhibitor (C1-INH) Replacement Therapy for Routine Prevention of Attacks in Patients with Hereditary Angioedema (HAE)
Authors: Jonathan A. Bernstein, Huamin Henry Li, Timothy J. Craig, Hilary J. Longhurst, Henriette Farkas, Michael E. Manning, Thomas Machnig, John-Philip Lawo, Dipti Pawaskar, Iris Jacobs
Journal: Journal of Allergy and Clinical Immunology (2017)
Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,
Authors: Anna Guidetti, Silvia Locatelli, Simonetta Viviani, Anna Dodero, Lucia Farina, Domenico Russo, Pietro Bulian, Roberto Sorasio, Massimo Di Nicola, Paolo Corradini, Andrea Anichini, Alessandro M. Gianni, Carmelo Carlo-Stella
Journal: Blood (2011)
Effects of beyond KRAS mutations on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases (BELIEF): a retrospective biomarker analysis from a Chinese trial
Authors: J. Xu, L. Ren, Y. Wei, P. Zheng, L. Ye, Q. Feng, Q. Lin, D. Zhu, W. Chang, M. Ji
Journal: Annals of Oncology (2016)
A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacokinetics, immunohistochemistry, and quantitative tumor uptake
Authors: J. Sakamoto, N. Oriuchi, E. Mochiki, A. M. Scott, E. Hoffman, A. Jungbluth, A. Asao, H. Kuwano, K. Endo, L. J. Old
Journal: Journal of Clinical Oncology (2004)

4142 Background: An open label dose escalation biopsy-based Phase I trial of huA33 in patients with early gastric carcinoma Methods: Thirteen patients were entered onto one of four dose levels (1.0, 2.0, 5.0, 10.0mg/m2.Patients with early gastric carcinoma received infusion of 131I-huA33 one week prior to surgery. Adverse events, imaging studies, biodistribution, tumor biopsies, and immunohistochemical analysis were performed and evaluated. Results: No dose-limiting toxicity was observed during the trial; the maximum tolerated dose was therefore not reached. Although cancer tissues with (+) or (±) by immunostaining in biopsied frozen sections did not show positive imaging or postoperative dosimetry findings, cancers with (++) or (+++) by frozen and paraffin sections in the biopsied specimen showed positive ex-vivo scan and positive antigen expression in resected gastric cancer specimen, and the biodistribution of the huA33 showed uptake of 131I-huA33. Conclusions: Humanized monoclonal antibody huA33 demonstrated selective localization to gastric cancer that strongly expresses A33 antigen. These excellent targeting characteristics of the huA33 indicate potential for the targeted therapy of advanced gastric cancer that is refractory to cytotoxic therapy, and could also be exploitable for curatively resected early gastric cancer in an adjuvant setting. No significant financial relationships to disclose.
Different clinical characteristics in biliary tract cancers
Authors: M. A. Lee, I. S. Woo, J. H. Kang, Y. S. Hong, K. S. Lee, D. G. Kim, S. N. Kim, S. Y. Park, S. Y. Kim
Journal: Journal of Clinical Oncology (2005)

4215 Background: Biliary tract cancer (BTC) includes intrahepatic cholangiocarcinoma, Klastkin tumor, extrahepatic cholangiocarcinoma, gall bladder cancer and ampulla of Vater cancer. These cancers are usually not common, and classified as resistant cancer. In many clinical trials, all type of BTC is approached with same protocol, although each cancer has different response to anti-cancer treatment. In the present study, we evaluated clinical course and characteristics of BTC after potentially curative resection to know the differences between BTC. Methods: Between October 1994 and December 2003 in Kangnam St. Mary’s hospital, patients, who underwent potentially curative resection with BTC, were enrolled. We reviewed the patients’ clinical record and analyzed clinical characteristics. We classified the recurrence pattern as 3 type, recurrence at anastomosis site, liver and biliary tract recurrence, and distant other organ metastasis. Results: Of total 177 patients, male was 110, and female was 67. Gall bladder cancer (54, 30.5%) is most common, and the next is extrahepatic cholangiocarcinoma (45, 24.5%). Except gall bladder cancer, male was more common than female. Median age was 61(58–62), and no difference found between each cancer of BTC. After surgery, 53(30%) patients took adjuvant treatment, using 5-FU-based chemotherapy or radiotherapy. There is no significant difference in recurrence rate, but recurrence pattern is different according to cancer type (p=0.028). Gall bladder cancer and ampulla of Vater cancer had recurrence in distant organ and liver metastasis more than local recurrence. There is no difference in pathological characteristics. Conclusions: In BTC, gall bladder cancer is most common. In aspect of clinical findings, no statistically significance found except recurrence pattern. After potentially curative resection, recurrence pattern is different according to each type of cancer. These results suggest that different approach to adjuvant treatment modality may be established for BTC. We are ongoing to perform protein expression to determine special characteristics of each cancer. No significant financial relationships to disclose.
Activating JAK3 Mutations in Transient Myeloproliferative Disorder and Acute Megakaryoblastic Leukemia Accompanying Down Syndrome.
Authors: Tomohiko Sato, Tsutomu Toki, Rika Kanezaki, Gang Xu, Kiminori Terui, Takuya Kamio, Seiji Kojima, Hitoshi Kiyoi, Hiroyuki Mano, Etsuro Ito
Journal: Blood (2007)
Radioimmunotherapy with I131 Tositumomab in Relapsed and Transformed Low-Grade (LG) Non-Hodgkin’s Lymphoma (NHL): Long-Term Follow-Up of a Single Institution Experience.
Authors: Huma Qawi, Teresa M. O’Brien, Parameswaran Venugopal, Jamile Shammo, Elena Bogdanova, Stephanie A. Gregory
Journal: Blood (2004)
Chemotherapy dose selection in a diverse sample of medically underserved women with breast cancer.
Authors: Jennifer J. Griggs, Melony S. Sorbero, Yihang Liu, Rose C. Maly
Journal: Journal of Clinical Oncology (2012)

221 Background: Black race, lower socioeconomic status, and obesity have been associated with reduced first cycle doses of adjuvant chemotherapy. There are no data on dosing patterns in Hispanics. The purpose of this study was to investigate chemotherapy dose selection among a diverse sample of patients treated for breast cancer through the Breast and Cervical Cancer Prevention Treatment Act (BCCPT) in the state of California from February 2003 to September 2005. Methods: Extensive medical record review of patients who received chemotherapy was performed. We calculated the first cycle dose ratio by dividing the actual doses of chemotherapy delivered by the expected doses. Expected doses were those in standard chemotherapy regimens. Bivariate and multivariate regression analyses were performed to identify clinical and non-clinical factors associated with dose reductions. Results: Among 658 patients with stages I to III breast cancer in the sample, 522 received chemotherapy. After exclusions, the final analytic sample included 403 women (122 non-Hispanic whites, 21 non-Hispanic blacks, 226 Hispanics, 28 Asians, and 6 of other races). Dose ratios &lt; 0.9 were given to 57 patients (14%). In bivariate analyses, race/ethnicity (p=0.004), body mass index (p&lt; 0.001), comorbidity (p&lt; 0.001), and treatment at a non-academic site (p=0.015) were associated with a dose ratio &lt; 0.9. Hispanics and Asians were least likely to have dose reductions. In multivariable analysis, only comorbidity (p=0.03), severe obesity (p=0.003), and being treated at a non-academic center (p=0.03) remained significantly associated with dose reductions. Race/ethnicity was no longer associated with dose selection. Conclusions: The majority of women diagnosed and treated through the BCCTP received high quality chemotherapy. Clinical factors (comorbidity and obesity) as well as site of care were associated with chemotherapy dose selection. The processes and resources in place at academic medical centers may account for the role of treatment site in quality of chemotherapy dose selection. Efforts to standardize dose selection across obesity status and treatment facilities are warranted.
5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia.
Authors: Jatinder K. Lamba, Amit Mitra, Kristine Crews, Stanley Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz, Raul C Ribeiro
Journal: Blood (2009)